REVIEW ARTICLE
Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data
M.H.A. Rustin,
M.H.A. Rustin
Royal Free London Foundation NHS Trust, Pond Street, London NW3 2QG, U.K.
Search for more papers by this authorM.H.A. Rustin,
M.H.A. Rustin
Royal Free London Foundation NHS Trust, Pond Street, London NW3 2QG, U.K.
Search for more papers by this authorM.H.A. Rustin. E-mail: [email protected]
Funding sources Editorial support for this article was funded by Janssen. Editorial control resided with the author. The author received no honoraria or other form of financial support related to the development of this manuscript. Financial support for publication of this supplement was provided by Janssen.
Conflicts of interest M.H.A.R. has been involved in clinical trials of all the biologicals mentioned in this review, has received honoraria for speaking at meetings organized by Janssen-Cilag and has received sponsorship from Schering-Plough, Abbott and Janssen-Cilag to attend scientific meetings.
Summary
Conventional non-biologic systemic agents are regarded as second-line therapy for the treatment of moderate-to-severe plaque psoriasis after topical treatments. However, long-term data have highlighted a number of safety concerns associated with their prolonged use. Biologic agents targeting specific immune mediators have emerged as an alternative treatment option for patients with moderate-to-severe plaque psoriasis who are unresponsive to, or intolerant of, non-biologic systemic agents. Although several biologics have demonstrated good efficacy and tolerability in short-term trials, treatment guidelines recommend them as third-line therapies due to a relative lack of long-term safety data. Here, we have reviewed the long-term (≥ 1 year) safety data from randomized controlled trials, open-label extension studies and meta-analyses of etanercept, infliximab, efalizumab, adalimumab, alefacept and ustekinumab in the treatment of adults with moderate-to-severe plaque psoriasis. With the exception of efalizumab, which has been withdrawn from both the European and U.S. markets due to long-term safety concerns, these biologics are generally well tolerated in long-term studies, and offer a viable alternative to conventional non-biologic agents in patients with moderate-to-severe plaque psoriasis.
References
- 1 Gelfand JM, Neimann AL, Shin DB et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735–41.
- 2 Gelfand JM, Troxel AB, Lewis JD et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007; 143: 1493–9.
- 3 Kurd SK, Troxel AB, Crits-Christoph P et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 2010; 146: 891–5.
- 4 Strober BE, Siu K, Menon K. Conventional systemic agents for psoriasis. A systematic review. J Rheumatol 2006; 33: 1442–6.
- 5 Griffiths CEM, Clark CM, Chalmers RJ et al. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000; 4: 1–125.
- 6 Papp KA. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res 2006; 298: 7–15.
- 7 Dommasch ED, Abuabara K, Shin DB et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 2011; 64: 1035–50.
- 8 Kwon HJ, Coté TR, Cuffe MS et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138: 807–11.
- 9
Mohan N,
Edwards ET,
Cupps TR
et al.
Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.
Arthritis Rheum
2001; 44: 2862–9.
10.1002/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W CAS PubMed Web of Science® Google Scholar
- 10 Bongartz T, Sutton AJ, Sweeting MJ et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275–85.
- 11 Mariette X, Matucci-Cerinic M, Pavelka K et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011; 70: 1895–904.
- 12 Grijalva CG, Chen L, Delzell E et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306: 2331–9.
- 13 Ryan C, Leonardi CL, Krueger JG et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 2011; 306: 864–71.
- 14 Tzellos T, Kyrgidis A, Zouboulis CC. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol 2012; 2012 Mar 8. doi: 10.1111/j.1468-3083.2012.04500.x. [Epub ahead of print]
- 15 Kothary N, Diak IL, Brinker A et al. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol 2011; 65: 546–51.
- 16 Papp KA, Poulin Y, Bissonnette R et al. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol 2012; 66: e33–45.
- 17 Papp KA, Tyring S, Lahfa M et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304–12.
- 18 Leonardi C, Strober B, Gottlieb AB et al. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol 2010; 9: 928–37.
- 19 Tyring S, Gordon KB, Poulin Y et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143: 719–26.
- 20 Paller AS, Siegfried EC, Eichenfield LF et al. Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Dermatol 2010; 63: 762–8.
- 21 Menter A, Feldman SR, Weinstein GD et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56: 31.e1–15.
- 22 Torii H, Nakagawa H. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci 2010; 59: 40–9.
- 23 Gordon KB, Langley RG, Leonardi C et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598–606.
- 24 Menter A, Tyring SK, Gordon K et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106–15.
- 25 van de Putte LB, Atkins C, Malaise M et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004; 63: 508–16.
- 26 Gordon K, Papp K, Poulin Y et al. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol 2012; 66: 241–51.
- 27 Leonardi C, Menter A, Hamilton T et al. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol 2008; 158: 1107–16.
- 28 Carr D, Tusa MG, Carroll CL et al. Open label trial for alefacept in palmoplantar pustular psoriasis. J Dermatolog Treat 2008; 19: 97–100.
- 29 Shah A, O’Neill J, Feldman SR. Treatment of moderate-to-severe psoriasis with alefacept for up to one year: a case series. J Drugs Dermatol 2010; 9: 1491–4.
- 30 Roberts JL, Ortonne J-P, Jerry KL et al. The safety profile and sustained remission associated with response to multiple courses of intramuscular alefacept for treatment of chronic plaque psoriasis. J Am Acad Dermatol 2010; 62: 968–78.
- 31 Krueger GG, Gottlieb AB, Sterry W et al. A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis. J Dermatolog Treat 2008; 19: 146–55.
- 32 Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665–74.
- 33 Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675–84.
- 34 Lebwohl M, Leonardi C, Griffiths CE et al. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol 2012; 66: 731–41.
- 35 Gordon KB, Papp KA, Langley RG et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol 2012; 66: 742–51.
- 36 Reich K, Langley RG, Lebwohl M et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol 2011; 164: 862–72.
- 37 Reich K, Papp KA, Griffiths CE et al. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol 2012; 11: 300–12.
- 38 Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987–1019.
- 39 Pathirana D, Ormerod AD, Saiag P et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl. 2): 1–70.
- 40 Merck Sharp & Dohme Ltd. Remicade: summary of product characteristics. Available at: http://www.medicines.org.uk/emc/medicine/3236/SPC (last accessed 1 August 2012).
- 41 Pfizer Ltd. Enbrel: summary of product characteristics. Available at: http://www.medicines.org.uk/emc/medicine/3343/SPC (last accessed 1 August 2012).
- 42 AbbVie Limited. Humira: summary of product characteristics. Available at: http://www.medicines.org.uk/emc/medicine/21201/SPC (last accessed 1 August 2012).
- 43 Janssen-Cilag Ltd. Stelara: summary of product characteristics. Available at: http://www.medicines.org.uk/emc/medicine/23207/SPC (last accessed 1 August 2012).
- 44 Verstappen SM, King Y, Watson KD et al. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70: 823–6.
- 45 Vasiliauskas EA, Church JA, Silverman N et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006; 4: 1255–8.
- 46 Domm S, Cinatl J, Mrowietz U. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008; 159: 1217–28.
- 47 Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005; 42: 315–22.
- 48 Barco D, Puig L, Alomar A. Treatment of moderate-severe psoriasis with etanercept in patients with chronic human immunodeficiency virus infection. Actas Dermosifiliogr 2010; 101 (Suppl. 1): 77–81.
- 49 Galloway JB, Hyrich KL, Mercer LK et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70: 1810–4.
- 50 Powles AV, Hardman CM, Porter WM et al. Renal function after 10 years’ treatment with cyclosporin for psoriasis. Br J Dermatol 1998; 138: 443–9.
- 51 Paul CF, Ho VC, McGeown C et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003; 120: 211–6.
- 52 Kuijpers AL, van de Kerkhof PC. Risk–benefit assessment of methotrexate in the treatment of severe psoriasis. Am J Clin Dermatol 2000; 1: 27–39.
- 53 Rothman KJ, Moore LL, Singer MR et al. Teratogenicity of high vitamin A intake. N Engl J Med 1995; 333: 1369–73.
- 54 Nijsten T, Margolis DJ, Feldman SR et al. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol 2005; 52: 434–44.
- 55 Reich K, Signorovitch J, Ramakrishnan K et al. Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial. J Am Acad Dermatol 2010; 63: 1011–8.
- 56 Schmitt J, Zhang Z, Wozel G et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159: 513–26.
- 57 Brimhall AK, King LN, Licciardone JC et al. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159: 274–85.
- 58 Strangfeld A, Listing J, Herzer P et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009; 301: 737–44.
- 59 Dixon WG, Hyrich KL, Watson KD et al. Drug specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy; results from the BSR biologics register (BSRBR). Rheumatology 2008; 47: 171.
- 60 Griffiths CEM, Strober BE, van de Kerkhof P et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118–28.
